ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Septerna, a biotechnology company focused on developing new small-molecule drugs for G-protein-coupled receptors (GPCRs), has sold a GPCR program to Vertex Pharmaceuticals for $47.5 million. Vertex sells several cystic fibrosis therapies and is pursuing treatments for other diseases. The agreement, announced just 2 months after Septerna closed a $150 million round of series B funding, concerns a discovery-stage Septerna program targeting an undisclosed receptor. If the program meets preclinical milestones, Septerna stands to earn additional payouts.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter